MRI Accuracy for Recurrence After Partial Gland Ablation with HIFU for Localized Prostate Cancer. A Systematic Review and Meta-analysis

Overview

Journal Prostate Cancer Prostatic Dis

Specialties Oncology
Urology

Date 2024 Sep 10

PMID 39256551

Authors

Denis Seguier

Philippe Puech

Eric Barret

Xavier Leroy

Julien Labreuche

Raphael Renard Penna

Guillaume Ploussard

Arnauld Villers

Jonathan Olivier

Affiliations

Soon will be listed here.

Abstract

Background: Prostate cancer remains the most frequently diagnosed cancer among men. High-Intensity Focused Ultrasound (HIFU) has emerged as a thermal ablative technique for partial-gland-ablation (PGA), aiming to minimize collateral damage while maximizing tumor control. Monitoring after HIFU PGA relies on serial PSA testing, multiparametric-MRI, and biopsies. The diagnostic accuracy of MRI for clinically-significant cancer(csPCa) recurrence is challenging.

Objective: This systematic review and meta-analysis aim to evaluate the accuracy of MRI in detecting early recurrence of localized prostate cancer following HIFU PGA.

Methods: Adhering to PRISMA guidelines, a comprehensive literature search was conducted until May 8 2024 using MEDLINE and Scopus. The inclusion criteria encompassed randomized controlled trials and cohort studies involving men diagnosed with localized prostate cancer who had as primary treatment HIFU PGA. The primary outcome measures included the sensitivity, specificity, positive-predictive value (PPV), and negative-predictive value (NPV) of MRI for csPCa(ISUP ≥ 2) based on biopsy results. We pooled data from studies with sufficient csPCa and csPCa-free patients (≥5) post HIFU for statistical analysis.

Results: Fifteen studies meet the inclusion criteria, encompassing 1093 patients and 12 studies were eligible for meta-analysis. MRI sensitivity in detecting clinically-significant prostate cancer (csPCa) recurrence post HIFU PGA varied widely (0-89%), with a pooled sensitivity of 0.52 (95% CI:0.36-0.68). Specificity ranged from 44% to 100%, with a pooled specificity of 0.81 (95% CI:0.68-0.91). The pooled NPV was 0.82 (95% CI:0.72-0.90), and the pooled PPV was 0.50 (95% CI:0.35-0.65). Three studies reported in-field diagnostic performance with sensitivities ranging from 0.42 to 0.80 and specificities from 0.45 to 0.97.

Conclusion: MRI accuracy for clinically-significant recurrence after partial gland ablation with HIFU for localized prostate cancer shows low diagnostic performance in the treated lobe with pooled sensitivity of 0.52 (95% CI:0.36-0.68) and specificity of 0.81 (95% CI:0.68-0.91). Limits of this review include the low number of studies reporting about site of recurrence in or out of the treated lobe.

Citing Articles

Focal Therapy for Prostate Cancer: Recent Advances and Insights.

Lasorsa F, Biasatti A, Orsini A, Bignante G, Farah G, Pandolfo S Curr Oncol. 2025; 32(1).

PMID: 39851931 PMC: 11764426. DOI: 10.3390/curroncol32010015.

References

Valerio M, Cerantola Y, Eggener S, Lepor H, Polascik T, Villers A . New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Eur Urol. 2016; 71(1):17-34. DOI: 10.1016/j.eururo.2016.08.044. View

Ploussard G, Fiard G, Barret E, Brureau L, Crehange G, Dariane C . French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease. Prog Urol. 2022; 32(15):1275-1372. DOI: 10.1016/j.purol.2022.07.148. View

Huber P, Afzal N, Arya M, Boxler S, Dudderidge T, Emberton M . Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound. J Urol. 2020; 203(4):734-742. DOI: 10.1097/JU.0000000000000747. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A . Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016; 5(1):210. PMC: 5139140. DOI: 10.1186/s13643-016-0384-4. View

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View

Tay K, Schulman A, Sze C, Tsivian E, Polascik T . New advances in focal therapy for early stage prostate cancer. Expert Rev Anticancer Ther. 2017; 17(8):737-743. DOI: 10.1080/14737140.2017.1345630. View

Dickinson L, Ahmed H, Hindley R, McCartan N, Freeman A, Allen C . Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer. Urol Oncol. 2016; 35(1):30.e9-30.e15. DOI: 10.1016/j.urolonc.2016.07.015. View

Lotte R, Lafourcade A, Mozer P, Conort P, Barret E, Comperat E . Multiparametric MRI for Suspected Recurrent Prostate Cancer after HIFU:Is DCE still needed?. Eur Radiol. 2018; 28(9):3760-3769. DOI: 10.1007/s00330-018-5352-z. View

10.

Rosenhammer B, Niessen C, Rotzinger L, Reiss J, Schnabel M, Burger M . Oncological Outcome and Value of Postoperative Magnetic Resonance Imaging after Focal High-Intensity Focused Ultrasound Therapy for Prostate Cancer. Urol Int. 2019; 103(3):270-278. DOI: 10.1159/000502553. View

11.

Bass R, Fleshner N, Finelli A, Barkin J, Zhang L, Klotz L . Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer. J Urol. 2018; 201(1):113-119. DOI: 10.1016/j.juro.2018.07.040. View

12.

Mortezavi A, Krauter J, Gu A, Sonderer J, Bruhin J, Reeve K . Extensive Histological Sampling following Focal Therapy of Clinically Significant Prostate Cancer with High Intensity Focused Ultrasound. J Urol. 2019; 202(4):717-724. DOI: 10.1097/JU.0000000000000298. View

13.

Shoji S, Hiraiwa S, Uemura K, Nitta M, Hasegawa M, Kawamura Y . Focal therapy with high-intensity focused ultrasound for the localized prostate cancer for Asian based on the localization with MRI-TRUS fusion image-guided transperineal biopsy and 12-cores transperineal systematic biopsy: prospective analysis of.... Int J Clin Oncol. 2020; 25(10):1844-1853. DOI: 10.1007/s10147-020-01723-9. View

14.

Bacchetta F, Martins M, Regusci S, Jichlinski P, Meuwly J, Lucca I . The utility of intraoperative contrast-enhanced ultrasound in detecting residual disease after focal HIFU for localized prostate cancer. Urol Oncol. 2020; 38(11):846.e1-846.e7. DOI: 10.1016/j.urolonc.2020.05.010. View

15.

Rompre-Brodeur A, Marcq G, Tholomier C, Fugaru I, Loutochin O, Anidjar M . Role of Systematic Control Biopsies following Partial Gland Ablation with High-Intensity Focused Ultrasound for Clinically Significant Prostate Cancer. J Urol. 2021; 206(5):1177-1183. DOI: 10.1097/JU.0000000000001934. View

16.

Yee C, Chiu P, Teoh J, Ng C, Chan C, Hou S . High-Intensity Focused Ultrasound (HIFU) Focal Therapy for Localized Prostate Cancer with MRI-US Fusion Platform. Adv Urol. 2021; 2021:7157973. PMC: 8692047. DOI: 10.1155/2021/7157973. View

17.

Ahn H, Hwang S, Lee H, Kim S, Cho J, Lee H . Diagnostic performance of MRI for prediction of recurrent prostate cancer after high-intensity focused ultrasound: a systematic review and meta-analysis. Prostate Int. 2023; 11(2):59-68. PMC: 10318330. DOI: 10.1016/j.prnil.2022.12.004. View

18.

Khandwala Y, Morisetty S, Ghanouni P, Fan R, Soerensen S, Rusu M . Evaluation of post-ablation mpMRI as a predictor of residual prostate cancer after focal high intensity focused ultrasound (HIFU) ablation. Urol Oncol. 2022; 40(11):489.e9-489.e17. PMC: 10058305. DOI: 10.1016/j.urolonc.2022.07.017. View

19.

Pausch A, Elsner C, Rupp N, Eberli D, Hotker A . MRI-based monitoring of prostate cancer after HIFU: Inter-reader agreement and diagnostic performance of the PI-FAB score. Eur J Radiol. 2024; 175:111463. DOI: 10.1016/j.ejrad.2024.111463. View

20.

Dellabella M, Branchi A, Di Rosa M, Pucci M, Gasparri L, Claudini R . Oncological and functional outcome after partial prostate HIFU ablation with Focal-One: a prospective single-center study. Prostate Cancer Prostatic Dis. 2021; 24(4):1189-1197. DOI: 10.1038/s41391-021-00390-9. View